MedTrace Logo

A Phase I Clinical Study of the Safety, Tolerability and Pharmacokinetics of HX-1171 in Healthy Male Subjects.

NCT01889745 · Status: TEMPORARILY_NOT_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2013-06-28

No results posted yet for this study

Summary

This study is designed to multiple dose and dose escalation study

Conditions

  • Healthy

Interventions

DRUG

HX-1171

Anti-oxidatant, Anti-inflamation

Sponsors & Collaborators

  • Biotoxtech Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Kyun-Seop Bae, M.D., Ph.D · Asan Medical Center

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • South Korea

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01889745 on ClinicalTrials.gov